Overview
Spear Bio offers SPEAR UltraDetect, a homogeneous immunoassay platform for ultrasensitive protein biomarker detection using patented two-factor authentication and qPCR amplification. It enables attomolar sensitivity from 1 µL samples, targeting neurology biomarkers like pTau231, pTau217, GFAP, and NfL for neurodegenerative disease research. The technology supports research-use-only applications with services for custom assay development and biomarker analysis.
Frequently asked questions
- What biomarkers does Spear Bio's SPEAR UltraDetect target?
- Initial assays target neurology biomarkers: phosphorylated tau 231 (pTau231), phosphorylated tau 217 (pTau217), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).
- What is the sensitivity and sample requirement for SPEAR assays?
- SPEAR UltraDetect achieves attomolar biomarker measurement with 1 µL of diluted sample, offering high specificity via two-factor authentication and low CV (<5%) in a wash-free workflow.
- What services does Spear Bio provide for custom needs?
- Services include platform evaluation, custom assay development, and biomarker analysis to support academic research and publications.